US$ 24.26
glp-1 shortage The promise and peril of agonists: What we do (and don't) know as of August 2024 The GLP-1 boom created one
Description
There are a few others, but these are the most commonly talked about and prescribed today, so well focus on them
Canadian Journal of Cardiology 37140150

Fundoscopy included assessment of absence or presence of papilledema and secondary optic atrophy

An important feature of GLP-1 RA use in type 2 diabetes is weight loss, which reduces insulin resistance and typically reaches a plateau after around 6 months of treatment

24 Small molecules may offer advantages such as improved tissue permeability, longer half-lives, and lower production costs
